Review decision - June 2022

Decision that the existing guidance remains relevant and an update is not needed

We would like to update you on the decision made regarding the review of the existing NICE technology appraisal guidance TA188 on human growth hormone (somatropin) for the treatment of growth failure in children.

No substantial new evidence has been identified that would be likely to change the current recommendation in TA188, therefore it is concluded that an update is not needed. The new licensed indication for somatropin and the new long-acting growth hormone considered within this review are recommended for consideration as new single technology appraisals rather than within a review of TA188.

The guidance will remain unchanged, in its current form, unless or until NICE becomes aware of substantive information which would make it reconsider.

Review decision paper

This page was last updated: